Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Articles|June 15, 2026
This Week on NeurologyLive® — June 15, 2026
Author(s)Isabella Ciccone, MPH
Listen
0:00 / 0:00
Key Takeaways
- NeurologyLive curates a weekly forward-looking snapshot to orient readers to imminent clinical and industry coverage.
- Several high-interest neurology topics are scheduled for posting, with additional reporting available beyond the featured highlights.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive, there are a number of hot topics that we will be posting on the website. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!
Click through the slides below to see what you can expect from our team this week. Click any slide to check out the content.
—————————————————
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
4
Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy
5